Advertisement

Topics

Boehringer initiates phase 1 trials of Zealand’s analogs for obesity and diabetes

05:13 EDT 23 Aug 2017 | Pharmaceutical Business Review

Zealand Pharma says that its partner Boehringer Ingelheim has launched phase 1 clinical trials to assess glucagon/GLP-1 agonist and an amylin analog as new treatment options for obesity and diabetes.

Original Article: Boehringer initiates phase 1 trials of Zealand’s analogs for obesity and diabetes

NEXT ARTICLE

More From BioPortfolio on "Boehringer initiates phase 1 trials of Zealand’s analogs for obesity and diabetes"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...